Drug therapy for the management of cancer related fatigue (Q24242050)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article (publication date: 23 January 2008)

Language	Label	Description	Also known as
English	Drug therapy for the management of cancer related fatigue	scientific article (publication date: 23 January 2008)

Statements

scholarly article

0 references

0 references

1 reference

Europe PubMed Central

Drug therapy for the management of cancer related fatigue (English)

0 references

5

object named as

Matthew Hotopf

0 references

4

object named as

Michael Sharpe

0 references

Alison Richardson

3

object named as

Alison Richardson

0 references

author name string

Ollie Minton

1

0 references

Patrick Stone

2

0 references

publication date

23 January 2008

0 references

Cochrane Database of Systematic Reviews

0 references

Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Impact of epoetin beta on quality of life in patients with malignant disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Fluoxetine Versus Placebo in Advanced Cancer Outpatients: A Double-Blinded Trial of the Hoosier Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Exercise for treatment of cancer related fatigue

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

A population-based incidence study of chronic fatigue.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Evidence-based treatment for cancer-related fatigue

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Fatigue associated with cancer and its treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Management of cancer-related fatigue

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Drugs for the treatment of fatigue in palliative care

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Fatigue after breast cancer and in chronic fatigue syndrome: similarities and differences

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

The measurement, causes and effective management of cancer-related fatigue

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

21 January 2018

Fatigue in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Corticosteroid therapy of preterminal gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatigue and psychological distress in the working population

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006704.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD006704.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24242050&oldid=2264339184"